{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["11(3)"],"submitter":["Karmarkar EN"],"funding":["National Center for Advancing Translational Sciences","Institute of Translational Health Sciences","National Institutes of Health","King Holmes Endowed Professorship held by J. C. D"],"pubmed_abstract":["<h4>Background</h4>Data on tecovirimat effectiveness for human mpox are limited. We conducted a retrospective cross-sectional interview-based study to identify associations between tecovirimat treatment and the mpox clinical course.<h4>Methods</h4>Using public health surveillance data from King County, Washington, we recruited and interviewed persons diagnosed with mpox during May-October 2022. We calculated descriptive statistics on demographics, vaccination status, comorbidities, and symptoms including 3 self-reported dates (symptom onset, first date of symptom improvement, and illness resolution). We used multivariable linear regression, stratified by illness severity, to evaluate the association of tecovirimat treatment with time to symptom improvement and time to illness resolution. W"],"journal":["Open forum infectious diseases"],"pagination":["ofae029"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10919389"],"repository":["biostudies-literature"],"pubmed_title":["Association of Tecovirimat Therapy With Mpox Symptom Improvement: A Cross-sectional Study-King County, Washington, May-October 2022."],"pmcid":["PMC10919389"],"pubmed_authors":["Kay MK","Ramchandani MS","Kerani RP","Chow EJ","Bender Ignacio RA","Dombrowski JC","Golden MR","Pogosjans S","Karmarkar EN","Cannon CA"],"additional_accession":[]},"is_claimable":false,"name":"Association of Tecovirimat Therapy With Mpox Symptom Improvement: A Cross-sectional Study-King County, Washington, May-October 2022.","description":"<h4>Background</h4>Data on tecovirimat effectiveness for human mpox are limited. We conducted a retrospective cross-sectional interview-based study to identify associations between tecovirimat treatment and the mpox clinical course.<h4>Methods</h4>Using public health surveillance data from King County, Washington, we recruited and interviewed persons diagnosed with mpox during May-October 2022. We calculated descriptive statistics on demographics, vaccination status, comorbidities, and symptoms including 3 self-reported dates (symptom onset, first date of symptom improvement, and illness resolution). We used multivariable linear regression, stratified by illness severity, to evaluate the association of tecovirimat treatment with time to symptom improvement and time to illness resolution. W","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2025-06-01T02:16:05.371Z","creation":"2024-11-14T22:26:07.302Z"},"accession":"S-EPMC10919389","cross_references":{"pubmed":["38456195"],"doi":["10.1093/ofid/ofae029"]}}